Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Omeros Corp

OMER ✗ NOT COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Small Cap Analyst: BUY

Last Close

$17.19

▼ -0.92%

Market Cap $1.24B · Vol 1.20M

Key Metrics

P/E Ratio

11.86

FWD: 18.62

Market Cap

$1.24B

Small Cap

Div Yield

N/A

EPS Growth

+1,700.00%

YoY

RSI (14)

91.26

Momentum

Beta

2.62

vs Market

52W High

$18.13

5.18% below

52W Low

$3.94

336.29% above

Volume

1.20M

Avg 621.65K

P/B

N/A

Price-to-book

ROE

N/A

Return on equity

Free Float

96.44%

Public shares

Shariah Compliance8 STANDARDS

✗ Omeros Corp (OMER) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does OMER pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+29.74%

+63.71%

+29.44%

+47.05%

YTD

+0.09%

+317.23%

+360.86%

+12.13%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-4,808,000.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-0.93% · N/A

P/E Ratio	11.86
Forward P/E (FY1)	18.62
PEG Ratio	N/A
P/S	N/A
P/B	N/A
P/FCF	N/A
EPS Growth	+1,700.00%
Outstanding Shares	72.39M

Technical Indicators

50-Day SMA	$10.90
200-Day SMA	$11.28
RSI (14)	91.26
Beta	2.62
52-Week High	$18.13
52-Week Low	$3.94

Volume Today	1.20M
Avg Daily Volume (30D)	621.65K
Relative Volume	1.93x
Volatility (10D)	110.57
Volatility (30D)	95.81
Free Float	96.44%

Analyst Consensus

BUY

Current Price $17.19

Mean Target $44.00

52W Low$3.94 52W High$18.13

Current

Target

$3.94 $18.13

Current Analyst target

+155.96% upside potential · 4 analysts

Identifiers

ExchangeNasdaq

FIGIBBG001SPJH21

ISINUS6821431029

CountryUnited States of America

Sub-IndustryBio Therapeutic Drugs

Earnings DateNov 13, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co Ltd -2.85% ARGX.BR argenx SE -3.21% ARGX argenx SE -0.66% INSM Insmed Inc -2.05% 2269.HK WuXi Biologics (Cayman) Inc -1.27%

Company Profile

Omeros Corporation is a clinical-stage biopharmaceutical company. The Company focuses on discovering, developing, and commercializing first-in-class small-molecule and protein therapeutics for both large-market and orphan indications, with a particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. Its clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program. Its commercial product, YARTEMLEA, is the approved inhibitor of the lectin pathway of complement. YARTEMLEA is used for the treatment of TA-TMA in adults and in children ages two years and older. YARTEMLEA selectively inhibits MASP-2, blocking pathway activation while preserving classical and alternative complement pathway functions.